CASI Pharmaceuticals Inc
CASI2.029USD
+0.739+57.29%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
31.43MCap. mercado
PérdidaP/E TTM
Más Datos de CASI Pharmaceuticals Inc Compañía
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Información de la empresa
Símbolo de cotizaciónCASI
Nombre de la empresaCASI Pharmaceuticals Inc
Fecha de salida a bolsaAug 23, 2021
Director ejecutivoDr. Wei-Wu He, Ph.D.
Número de empleados233
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 23
Dirección1701-1702, China Central Office Tower 1
CiudadBEIJING
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísChina
Código postal100025
Teléfono861065618789
Sitio Webhttps://www.casipharmaceuticals.com/
Símbolo de cotizaciónCASI
Fecha de salida a bolsaAug 23, 2021
Director ejecutivoDr. Wei-Wu He, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.52M
+11.33%
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
Mr. Wei (Larry) Zhang, Ph.D.
Mr. Wei (Larry) Zhang, Ph.D.
Senior Vice President
Senior Vice President
--
--
Ms. Chunhua Wang
Ms. Chunhua Wang
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Rui Zhang
Mr. Rui Zhang
Investor Relations
Investor Relations
--
--
Mr. Huang Hai
Mr. Huang Hai
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.52M
+11.33%
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 25 de jul
Actualizado: vie., 25 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
He (Wei-Wu)
22.69%
Panacea Venture Healthcare Fund I LP
13.23%
Foresite Capital Management, LLC
8.58%
Sparkle Byte Ltd
6.58%
VR Adviser, LLC
6.37%
Other
42.54%
Accionistas
Accionistas
Proporción
He (Wei-Wu)
22.69%
Panacea Venture Healthcare Fund I LP
13.23%
Foresite Capital Management, LLC
8.58%
Sparkle Byte Ltd
6.58%
VR Adviser, LLC
6.37%
Other
42.54%
Tipos de accionistas
Accionistas
Proporción
Corporation
25.68%
Individual Investor
22.70%
Venture Capital
12.28%
Private Equity
8.58%
Hedge Fund
1.62%
Investment Advisor
0.81%
Research Firm
0.21%
Investment Advisor/Hedge Fund
0.14%
Other
27.98%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
52
11.16M
72.02%
+1.11M
2025Q1
57
11.41M
73.67%
+1.54M
2024Q4
58
11.33M
84.52%
+2.13M
2024Q3
57
9.91M
73.95%
+2.26M
2024Q2
62
7.31M
54.55%
-1.23M
2024Q1
76
7.47M
55.75%
-860.83K
2023Q4
80
7.18M
53.75%
+54.06K
2023Q3
94
6.57M
49.20%
-572.41K
2023Q2
112
6.68M
49.99%
-822.50K
2023Q1
150
6.80M
50.47%
+209.73K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
He (Wei-Wu)
3.52M
22.69%
+357.64K
+11.33%
Jun 16, 2025
Panacea Venture Healthcare Fund I LP
1.32M
8.54%
+305.00K
+29.95%
Sep 30, 2024
Foresite Capital Management, LLC
1.33M
8.58%
--
--
Mar 31, 2025
Sparkle Byte Ltd
1.02M
6.58%
--
--
Mar 21, 2025
VR Adviser, LLC
987.26K
6.37%
--
--
Mar 31, 2025
IDG Capital Partners
915.85K
5.91%
+61.97K
+7.26%
Dec 30, 2024
Wealth Strategy Holding Ltd
908.79K
5.87%
--
--
Mar 21, 2025
Woodline Partners LP
164.37K
1.06%
+64.67K
+64.88%
Mar 31, 2025
Wellington Shields Capital Management, LLC
90.89K
0.59%
+5.06K
+5.89%
Mar 31, 2025
Adar1 Capital Management LLC
47.42K
0.31%
+1.10K
+2.37%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
Fecha
Tipo
Relación
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
